2 unchanged sentences
On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program, which was completed in January 2020, and $20.0 million reserved for open market repurchases which represents the maximum value of shares that may yet be purchased.
−Removed: No open market repurchases were made during the three-month period ended March 31, 2022.
+Added: No open market repurchases were made during the six-month period ended June 30, 2022.
Exhibit  
+Added: Anika Therapeutics, Inc.
+Added: 2017 Omnibus Incentive Plan (as amended effective June 8, 2022) (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed on June 10, 2022)
Rule 13a-14(a)/15d-14(a) Certifications
Certification of Dr.
−Removed: Blanchard, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Michael Levitz, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Blanchard, pursuant to Rules  
+Added: 13a-15(e)  
+Added: and 15d-15(e), as adopted pursuant to Section  
+Added: 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Michael Levitz, pursuant to Rules  
+Added: 13a-15(e)  
+Added: and 15d-15(e), as adopted pursuant to Section  
+Added: 302 of the Sarbanes-Oxley Act of 2002.
Section 1350 Certifications
1 unchanged sentence
Blanchard, and Michael Levitz, pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 as filed with the SEC on May 5, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:
−Removed: i.  
−Removed: Condensed Consolidated Balance Sheets as of March 31, 2022 (unaudited) and December 31, 2021 (unaudited)
−Removed: Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2022 and March 31, 2021 (unaudited)
−Removed: Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2022 and March 31, 2021 (unaudited)
−Removed: iv. Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2022 and March 31, 2021 (unaudited)
−Removed: Notes to Condensed Consolidated Financial Statements (unaudited)
−Removed: Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Added: Section  
+Added: 1350, as adopted pursuant to Section  
+Added: 906 of the Sarbanes-Oxley Act of 2002.
+Added: The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 as filed with the SEC on August 4, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:
+Added: Consolidated Balance Sheets as of June 30, 2022 (unaudited) and December 31, 2021 (unaudited)
+Added: Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2022 and June 30, 2021 (unaudited)
+Added: Consolidated Statements of Stockholders’ Equity for the Six Months Ended June 30, 2022 and June 30, 20201(unaudited)
+Added: Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and June 30, 2021 (unaudited)
+Added: Notes to Consolidated Financial Statements (unaudited)
+Added: Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) 
Filed herewith.
Furnished herewith.
+Added: Management contract or compensatory plan or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ANIKA THERAPEUTICS, INC.
+Added: August 4, 2022
/s/ MICHAEL LEVITZ
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.